Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the diabetic macular edema (dme) market?
The market size for Diabetic Macular Edema (DME) has seen a constant increase over the past few years. It’s projected to grow from $4.67 billion in 2024 to $4.89 billion in 2025, displaying a Compound Annual Growth Rate (CAGR) of 4.7%. The upward trend during the historic period is due to factors such as increased diabetes occurrences, a rise in edema-related issues, the growing number of diabetic eye disease cases, an increase in the aged population, and more cases of blindness.
What will be the diabetic macular edema (dme) market size in the future?
The market size for diabetic macular edema (DME) is forecasted to experience a steady expansion in the forthcoming years, reaching a size of $5.82 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.4%. The predicted growth in this period is due to factors such as enhanced access to healthcare services, increasing governmental healthcare investment, heightened awareness of diabetic complications, growing utilization of telemedicine for eye health, and the broadening of specific diabetic eye care centers. Key market trends expected over the forecast period involve the progress of anti-VEGF therapies, the use of corticosteroid implants, advancements in drug delivery methods, innovation in retinal laser procedures, the implementation of AI-powered diagnostic devices, and the adoption of less invasive surgical procedures.
Get your diabetic macular edema (dme) market report here!
https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report
What main drivers are fueling expansion in the diabetic macular edema (dme) market?
The diabetic macular edema (DME) market is forecasted to grow, driven by an increase in diabetes cases. This rise in diabetes can be linked to sedentary lifestyles, poor nutrition, increasing obesity, aging populations, and genetic factors. Diabetes impacts the eyes by damaging retinal blood vessels, which leads to fluid leak into the macula, leading to swelling, a condition known as diabetic macular edema. For example, as stated by the US-based Institute for Health Metrics and Evaluation in June 2023, over half a billion people were living with diabetes globally. This figure is predicted to more than double to encompass 1.3 billion inhabitants by 2050. For this reason, the diabetic macular edema (DME) market is growing progressively due to an increasing prevalence of diabetes.
What key areas define the segmentation of the global diabetic macular edema (dme) market?
The diabetic macular edema (DME) market covered in this report is segmented –
1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention
2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage
3) By Patient Demographics: Adults, Elderly, Children
4) By Route Of Administration: Intravitreal Injection, Topical, Systemic
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies
2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids
3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Surgical Intervention: Vitrectomy, Membrane Peeling
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21169&type=smp
Who are the dominant players expanding their reach in the diabetic macular edema (dme) market?
Major companies operating in the diabetic macular edema (DME) market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Carl Zeiss AG, Topcon Corporation, Ypsomed AG, ARKRAY Inc, Hugel Inc., Optos plc, Noven Pharmaceuticals Inc., Alimera Sciences Inc., Allergan plc.
What are the key trends shaping the future of the diabetic macular edema (dme) market?
Leading players in the DME treatment market are emphasizing technological advancements, such as enhanced drug therapies, to boost patient management and treatment results. These cutting-edge treatments leverage novel technology and research to address complex health issues more effectively. They strive for improved effectiveness, fewer side effects, and superior outcomes for patients. Notably, in March 2022, Novartis AG, a pharmaceutical firm from Switzerland, proclaimed the approval of Beovu by the European Commission for the treatment of visual impairment due to DME. This approval was granted on the basis of the results from Phase III KESTREL and KITE studies, which showed that Beovu’s effectiveness was on par with aflibercept in improving vision after one year. It is noteworthy that over half of the patients treated with Beovu adhered to a 12-week treatment schedule, recording fewer occurrences of retinal fluid compared to aflibercept.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21169
Which regions are emerging as leaders in the diabetic macular edema (dme) market?
North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (DME) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Antibody Contract Manufacturing Global Market Report 2025
Next-Generation Antibody Therapeutics Global Market Report 2025
Global Biosimilar Hormones Global Market Report 2025
https://thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
